The role of botulinum toxin type B (Myobloc) in the treatment of hyperkinetic facial lines.

Abstract

Botulinum toxin type B was studied for the management of hyperkinetic facial lines. It showed clinical longevity of up to 12 weeks on subjective rating scales and 8 weeks on objective rating scales. Botulinum toxin type B has shown relative safety but can have autonomic side effects at higher total doses, which limits the possibility of continued dose escalation. Although these findings may preclude its use as a primary modality for the use in hyperkinetic facial lines, botulinum toxin type B still has a role in the treatment of the aesthetic patient and is yet another tool in the armamentarium of aesthetic practitioners.